Cellosaurus logo
expasy logo

Cellosaurus RIL-175 (CVCL_B7TK)

[Text version]
Cell line name RIL-175
Synonyms RIL175
Accession CVCL_B7TK
Resource Identification Initiative To cite this cell line use: RIL-175 (RRID:CVCL_B7TK)
Comments Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53.
Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:5173; HRAS (Note=With p.Gly12Val).
Disease Hepatocellular carcinoma of the mouse (NCIt: C38756)
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: C57BL/6.
Hierarchy Children:
CVCL_B7TL (RIL-175-GM-CSF)CVCL_B7TM (RIL-175-KC)CVCL_B7TN (RIL175-R)
Category Cancer cell line
Publications

PubMed=23796475; DOI=10.1016/j.jhep.2013.06.010; PMCID=PMC3805787
Kapanadze T., Gamrekelashvili J., Ma C., Chan C., Zhao F., Hewitt S.M., Zender L., Kapoor V., Felsher D.W., Manns M.P., Korangy F., Greten T.F.
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
J. Hepatol. 59:1007-1013(2013)

DOI=10.5282/edoc.26548
Messner M.
Sorafenib resistance of hepatocellular carcinoma: antibiotics second- line to sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption.
Thesis PhD (2020); Ludwig Maximilians University of Munich; Munich; Germany

PubMed=32652772; DOI=10.1096/fj.202001128R
Messner M., Schmitt S., Ardelt M.A., Frohlich T., Muller M., Pein H., Huber-Cantonati P., Ortler C., Koenig L.M., Zobel L., Koeberle A., Arnold G.J., Rothenfusser S., Kiemer A.K., Gerbes A.L., Zischka H., Vollmar A.M., Pachmayr J.
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
FASEB J. 34:11860-11882(2020)

Cross-references
Encyclopedic resources Wikidata; Q114312786
Entry history
Entry creation23-Jun-2022
Last entry update19-Dec-2024
Version number6